The Korea Pharmaceutical and Bio-Pharma Association welcomed the launch of the National Bio Innovation Committee, saying it expects governance of the pharmaceutical and biotech sector to be unified.
In a statement issued on the 16th, the association said coordination among ministries and the government’s ability to execute policy would be strengthened, adding that it hopes policy goals and implementation plans will be pursued in a systematic way.
Earlier that day, the government held a launch ceremony for the committee at the Government Complex Sejong, chaired by Prime Minister Kim Min-seok. The committee was formed by integrating the separately run National Bio Committee and the Bio Health Innovation Committee, with the aim of overseeing and coordinating bio policy across the government.
The association said intensifying global technology competition has brought a shift across areas including new drug development, convergence with artificial intelligence and advanced manufacturing, underscoring the need for the committee.
It also said plans to expand open innovation based on cooperation among industry, academia, research institutes, hospitals and government, and to strengthen full-cycle support from research and development to commercialization, would help drive both expansion of the industry and qualitative growth.
The association also gave a positive assessment of measures such as AI-based support for R&D, building a national bio cluster and pursuing regulatory rationalization.
It said it hopes the committee will serve as a policy control tower and a focal point for strengthening national competitiveness, adding that it will actively cooperate for successful operations.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.